Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | Director | August 15, 2024 | August 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TREACE MEDICAL CONCEPTS, INC.
Report date August 15, 2024 · Filed August 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,223,441 |
Reported balance
After 2024-08-15 transaction · row 1
1 source rowRow 1 · 2024-08-15 · Purchase · Acquired 84,000 · Balance 1,223,441 F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.9100 to $6.0450 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 556,183 |
Reported balance
Holding disclosure · report date 2024-08-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 556,183 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.9100 to $6.0450 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2024 Filed Aug 19, 2024 09:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 84,000 | $5.96 | $501,034.80 |
DisclosureSEC source: 0000950170-24-098286 · ownership.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,223,441 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.9100 to $6.0450 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 16:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 25,000 | $6.05 | $151,327.50 |
DisclosureSEC source: 0000950170-24-068023 · ownership.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,139,441 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.9400 to $6.1800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2024 Filed May 30, 2024 17:04 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 25,000 | $5.20 | $130,062.50 |
DisclosureSEC source: 0000950170-24-066745 · ownership.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,114,441 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.1300 to $5.2900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2024 Filed May 29, 2024 16:33 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 50,000 | $5.07 | $253,475.00 |
DisclosureSEC source: 0000950170-24-065984 · ownership.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,089,441 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.9600 to $5.2000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| May 13, 2024 Filed May 13, 2024 19:47 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 145,000 | $4.54 | $657,981.00 |
DisclosureSEC source: 0000950170-24-058986 · ownership.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,039,441 F2 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3800 to $4.6400 0inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2024 Filed May 13, 2024 19:47 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 83,000 | $4.53 | $376,023.20 |
DisclosureSEC source: 0000950170-24-058986 · ownership.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894,441 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3300 to $4.7600 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 2, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 2,360 | $25.91 | $61,148.31 |
DisclosureSEC source: 0001209191-23-026796 · doc4.xml · nonDerivative · entry 3 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 861,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5400 to $26.1500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 2, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 7,640 | $25.04 | $191,282.68 |
DisclosureSEC source: 0001209191-23-026796 · doc4.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863,801 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.5400 to $25.5000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 28, 2023 Filed May 2, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 40,000 | $25.01 | $1,000,264.00 |
DisclosureSEC source: 0001209191-23-026796 · doc4.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 871,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.4100 to $25.3050 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 50,000 | $25.86 | $1,293,170.00 |
DisclosureSEC source: 0001209191-23-021955 · doc4.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5100 to $26.0700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 12,684 | $21.36 | $270,930.24 |
DisclosureSEC source: 0001209191-23-015075 · doc4.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 961,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.9700 to $21.5200 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 37,316 | $21.54 | $803,786.64 |
DisclosureSEC source: 0001209191-23-015075 · doc4.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.4100 to $22.2250 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 11,929 | $23.19 | $276,633.51 |
DisclosureSEC source: 0001209191-23-006465 · doc4.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.8000 to $23.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 30, 2023 Filed Jan 30, 2023 18:35 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon sotk | 1,054 | $24.55 | $25,879.71 |
DisclosureSEC source: 0001209191-23-005547 · doc4.xml · nonDerivative · entry 3 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,370 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.3600 to $25.0600 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 30, 2023 Filed Jan 30, 2023 18:35 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 8,803 | $23.68 | $208,411.91 |
DisclosureSEC source: 0001209191-23-005547 · doc4.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024,424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.3500 to $24.3300 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 30, 2023 Filed Jan 30, 2023 18:35 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 28,214 | $23.00 | $648,800.68 |
DisclosureSEC source: 0001209191-23-005547 · doc4.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,227 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.3500 to $23.3400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,000 | $24.18 | $604,575.00 |
DisclosureSEC source: 0001209191-22-061323 · doc4.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.8150 to $24.7050 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2022 Filed Mar 29, 2024 21:55 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 1,700 | $24.02 | $40,828.39 |
DisclosureSEC source: 0000950170-24-038822 · ownership.xml · nonDerivative · entry 4 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,036,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.6100 to $24.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2022 Filed Mar 29, 2024 21:55 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 200 | $21.97 | $4,394.00 |
DisclosureSEC source: 0000950170-24-038822 · ownership.xml · nonDerivative · entry 3 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,038,141 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 15, 2022 Filed Mar 29, 2024 21:55 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 1,600 | $21.18 | $33,890.08 |
DisclosureSEC source: 0000950170-24-038822 · ownership.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,038,341 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.6200 to $21.5400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2022 Filed Mar 29, 2024 21:55 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 46,500 | $20.12 | $935,580.00 |
DisclosureSEC source: 0000950170-24-038822 · ownership.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,039,941 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.55 to $20.4600 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 20, 2022 Filed Oct 21, 2022 20:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 8,742 | $23.02 | $201,235.59 |
DisclosureSEC source: 0001209191-22-054342 · doc4.xml · nonDerivative · entry 3 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,086,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.5000 to $23.3800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 10,861 | $23.37 | $253,863.93 |
DisclosureSEC source: 0001209191-22-054342 · doc4.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,183 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.2600 to $24.1900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 30,397 | $22.59 | $686,719.90 |
DisclosureSEC source: 0001209191-22-054342 · doc4.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106,044 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.1600 to $23.1200 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 22,645 | $23.27 | $526,980.85 |
DisclosureSEC source: 0001209191-22-050424 · doc4.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · shares: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.0900 to $23.4500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.0900 to $23.4500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 27,355 | $22.83 | $624,435.32 |
DisclosureSEC source: 0001209191-22-050424 · doc4.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.0900 to $23.0800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.0900 to $23.0800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 20:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 34,046 | $19.09 | $649,938.14 |
DisclosureSEC source: 0001209191-22-046956 · doc4.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,186,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.3400 to $19.2950 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 15,954 | $19.54 | $311,741.16 |
DisclosureSEC source: 0001209191-22-046956 · doc4.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220,487 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.0200 to $19.9000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 19:18 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 20,239 | $16.11 | $326,092.79 |
DisclosureSEC source: 0001567619-22-014272 · doc1.xml · nonDerivative · entry 3 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,236,441 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.62 to $16.54 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 19:18 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 983 | $16.46 | $16,177.03 |
DisclosureSEC source: 0001567619-22-014272 · doc1.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,256,680 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.39 to $16.51 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 19:18 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 12,978 | $16.06 | $208,400.72 |
DisclosureSEC source: 0001567619-22-014272 · doc1.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,663 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.38 to $16.37 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2022 Filed Jul 15, 2022 18:07 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 8,456 | $16.18 | $136,829.07 |
DisclosureSEC source: 0001567619-22-014078 · doc1.xml · nonDerivative · entry 3 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270,641 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.67 to $16.47 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 18:07 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 2,800 | $16.03 | $44,893.24 |
DisclosureSEC source: 0001567619-22-014078 · doc1.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279,097 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.60 to $16.25 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 18:07 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 4,544 | $16.13 | $73,283.36 |
DisclosureSEC source: 0001567619-22-014078 · doc1.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,897 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.82 to $16.3475 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 18:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 29,191 | $13.73 | $400,909.19 |
DisclosureSEC source: 0001567619-22-013208 · doc1.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286,441 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $13.52 to $14.00 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 20,809 | $13.58 | $282,573.73 |
DisclosureSEC source: 0001567619-22-013208 · doc1.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,315,632 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $13.33 to $14.04 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2022 Filed May 27, 2022 18:39 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 19,687 | $15.77 | $310,534.86 |
DisclosureSEC source: 0001567619-22-011883 · doc1.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,336,441 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.33 to $16.015 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 25, 2022 Filed May 27, 2022 18:39 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 30,313 | $15.35 | $465,322.74 |
DisclosureSEC source: 0001567619-22-011883 · doc1.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,356,128 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.06 to $15.71 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 18:01 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 2 | $19.21 | $38.41 |
DisclosureSEC source: 0001567619-22-006925 · doc1.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By J&A Group LLC Disclosed balance after: 0 F1 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company. Read SEC document |
| February 04, 2022 Filed Mar 14, 2022 18:01 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GiftCommon Stock | 450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006925 · doc1.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 556,183 Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 18:08 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 32,063 | $18.99 | $608,962.94 |
DisclosureSEC source: 0001567619-22-001384 · doc1.xml · nonDerivative · entry 3 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,386,441 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.4550 to $19.40 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 18:08 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 6,793 | $20.00 | $135,892.61 |
DisclosureSEC source: 0001567619-22-001384 · doc1.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,504 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.75 to $20.355 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 18:08 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 36,144 | $19.36 | $699,675.55 |
DisclosureSEC source: 0001567619-22-001384 · doc1.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,425,297 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.75 to $19.73 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 18:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 1,563 | $16.88 | $26,386.72 |
DisclosureSEC source: 0001567619-21-022714 · doc1.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By J&A Group LLC Disclosed balance after: 2 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.59 to $17.39 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company. Read SEC document |
| December 27, 2021 Filed Dec 27, 2021 20:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 6,437 | $17.46 | $112,377.79 |
DisclosureSEC source: 0001567619-21-022541 · doc1.xml · nonDerivative · entry 3 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By J&A Group LLC Disclosed balance after: 1,565 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.615 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company. Read SEC document |
| December 23, 2021 Filed Dec 27, 2021 20:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 12,610 | $16.90 | $213,159.44 |
DisclosureSEC source: 0001567619-21-022541 · doc1.xml · nonDerivative · entry 2 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By J&A Group LLC Disclosed balance after: 8,002 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.29 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 20:09 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 23,390 | $16.28 | $380,705.00 |
DisclosureSEC source: 0001567619-21-022541 · doc1.xml · nonDerivative · entry 1 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By J&A Group LLC Disclosed balance after: 20,612 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.59 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 19:03 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 1,403 | $16.36 | $22,952.66 |
DisclosureSEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 10 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By J&A Group LLC Disclosed balance after: 44,002 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.32 to $16.38 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 19:03 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 13,478 | $16.12 | $217,285.58 |
DisclosureSEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 9 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By J&A Group LLC Disclosed balance after: 45,405 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.32 to $16.31 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: James T. Treace and his spouse are managing members of J&A Group, LLC, a Florida limited liability company. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 19:03 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | OtherCommon Stock | 406,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-022459 · doc1.xml · nonDerivative · entry 8 TREACE JAMES T · CIK 0001185191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,461,441 F6 · kind: Includes pro rata distribution from J&A Group, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.